MedDataX Logo

Management of Nausea and Vomiting Chemotherapy-induced in Normandy

NCT ID: NCT01440465

Last Updated: 2025-12-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-07-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study was to evaluate the various parameters involved in the occurrence of nausea / vomiting during the first cycle of chemotherapy for solid tumors or hematologic among a group of chemotherapy-naive patients, despite anti standardized-emetics protocols.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Nausea Vomiting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged over 18 years
* With solid tumors or hematologic in first line chemotherapy, administered intravenously,
* Able to understand the meaning of the questions
* Having given their written consent to participate in the survey.

Exclusion Criteria

This does not concern patients who:

* Do not give their consent for participation
* Do not speak French
* Suffer from cognitive deficits
* Are under therapy
* Must receive a combination of radio-chemotherapy
* Present an occlusive syndrome
* Metastases (s) brain (s) clinically symptomatic (s) or radiologically proven (s) or a (of) tumor (s) brain (s)
* Have been previously treated with chemotherapy
* Present a cons-indication to corticosteroids, with anti-serotonin or NK1 receptor inhibitors
* Pregnant or breastfeeding.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Francois Baclesse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

JOLY Florence, Pr

Role: PRINCIPAL_INVESTIGATOR

Centre François Baclesse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre de la Baie

Avranches, , France

Site Status

Centre hospitalier

Bayeux, , France

Site Status

Centre Maurice Tubiana

Caen, , France

Site Status

Centre François Baclesse

Caen, , France

Site Status

Centre hospitalier public du cotentin

Cherbourg-Octeville, , France

Site Status

Centre Jacques Monod

Flers, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NAVI

Identifier Type: -

Identifier Source: org_study_id